熊海清

[摘要] 目的 分析不同剂量氨溴索口服液治疗糖尿病合并社区获得性肺炎（CAP）效果。方法 选取2015年12月—2017年12月间在该院接受治疗2型糖尿病合并CAP患者102例，随机数字表法将其分成两组，对照组（51例）口服1袋/次氨溴索口服液联合头孢替安治疗，观察组（51例）口服2袋/次氨溴索口服液联合头孢替安治疗；观察患者治疗前后临床效果及空腹、餐后2 h血糖含量状况。结果 观察组患者总的有效率为90.20%，高于对照组的66.67%，差异有统计学意义（P<0.05）；治疗前后两组患者空腹与餐后2 h血糖含量差异无统计学意义（P>0.05）。结论 大剂量氨溴索口服液较常规剂量对糖尿病合成CAP患者临床疗效更好，同时对患者血糖含量没有影响，安全性较高。

[关键词] 糖尿病；社区获得性肺炎；氨溴索口服液；不同剂量

[中图分类号] R563.1；R587.1 [文献标识码] A [文章编号] 1672-4062（2018）03（b）-0080-03

Analysis of Effect of Different Doses of Ambroxol Oral Liquid in Treatment of Diabetes Combined with Community Acquired Pneumonia

XIONG Hai-qing

Dong District Hongxing Community Health Service Center， Panzhihua， Sichuan Province， 617000 China

[Abstract] Objective To analyze the effect of different doses of ambroxol oral liquid in treatment of diabetes combined with community acquired pneumonia. Methods 102 cases of patients with type 2 diabetes combined with CAP treated in our hospital from December 2015 to December 2017 were selected and randomly divided into two groups with 51 cases in each， the control group took 1 bag of ambroxol oral liquid combined with cefotiam， each time， while the observation group took 2 bags of ambroxol oral liquid combined with cefotiam， and the clinical effect and fasting blood glucose and postprandial 2 h blood glucose contents before and after treatment of patients were observed. Results The total effective rate in the observation group was higher than that in the control group（90.20% vs 66.67%）， and the difference was statistically significant（P<0.05）， and the differences in the fasting blood glucose and postprandial 2 h blood glucose of the two groups before and after treatment were not statistically significant（P>0.05）. Conclusion The large-dose ambroxol oral liquid has a better clinical curative effect in treatment of patients with diabetes combined with CAP than the routine-dose ambroxol oral liquid， without any effect on the blood glucose content， and the safety is high.

[Key words] Diabetes； Community acquired pneumonia； Ambroxol oral liquid； Different doses

糖尿病為临床较为常见疾病，指由于胰岛素障碍或者胰岛素分泌障碍造成主要特征为高血糖代谢性疾病，而相关研究显示，肺部为糖尿病患者新靶器官。当前，伴随人们生活方式与饮食习惯变化，临床糖尿病患者逐年升高，相关统计显示，10%左右糖尿病患者因感染而死亡，其中肺部感染占据了45%，患者肺部感染病死率达到了41%左右，而社区获得性肺炎（Community-acquired pneumonia，CAP）为糖尿病合并肺部感染的主要类型[1-2]。氨溴索为临床常用祛痰止咳药物，能够使黏痰对呼吸道壁黏附影响下降，加速呼吸道纤毛上皮运动，使患者更容易把痰液咳出，确保气道通畅[3]。目前，临床对氨溴索不同剂量治疗糖尿病合并CAP治疗效果还未达成一致，因此，该文于2015年12月—2017年12月间通过分析不同剂量氨溴索口服液治疗糖尿病合并CAP效果，为临床患者治疗提供一些借鉴。……